Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia

Bioorg Med Chem Lett. 2012 Jan 1;22(1):235-9. doi: 10.1016/j.bmcl.2011.11.023. Epub 2011 Nov 16.

Abstract

A series of pyrazoloquinoline analogs have been synthesized and shown to bind to PDE10 with high affinity. From the SAR study and our lead optimization efforts, compounds 16 and 27 were found to possess potent oral antipsychotic activity in the MK-801 induced hyperactive rat model.

MeSH terms

  • Administration, Oral
  • Animals
  • Antipsychotic Agents / pharmacology*
  • Chemistry, Pharmaceutical / methods
  • Crystallography, X-Ray / methods
  • Disease Models, Animal
  • Dizocilpine Maleate / pharmacology
  • Drug Design
  • Excitatory Amino Acid Antagonists / pharmacology
  • Humans
  • Models, Chemical
  • Molecular Conformation
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphoric Diester Hydrolases / chemistry*
  • Pyrazoles / pharmacology*
  • Quinolines / pharmacology*
  • Rats
  • Schizophrenia / drug therapy*
  • Structure-Activity Relationship

Substances

  • Antipsychotic Agents
  • Excitatory Amino Acid Antagonists
  • Phosphodiesterase Inhibitors
  • Pyrazoles
  • Quinolines
  • Dizocilpine Maleate
  • PDE10A protein, human
  • PDE10A protein, rat
  • Phosphoric Diester Hydrolases